Pfizer Extends its Research and License Agreement with BioInvent to Develop Ab Targeting Tumor-Associated Myeloid Cells
Shots:
- Pfizer has selected its second target under the research and license agreement signed by the companies in 2016 and has extended the research term by six months
- BioInvent to receive $0.3M as target fees and will get milestones for the development of Ab directed against the target and is eligible to receive further milestones on the selection of additional targets
- In 2016- the companies collaborated to develop & commercialize Ab targeting tumor-associated myeloid cells discovered using BioInvent's F.I.R.S.T drug discovery platform. The platform allows the discovery of human Ab utilizing n-CoDeR Ab library to identify targets
Click here to read full press release/ article | Ref: PRNewswire | Image: BioInvent
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com